Reports
Reports
The artificial intelligence (AI) in drug discovery market is being fueled by growing costs and timelines to get new drugs to the market. Increased late-stage clinical trial failures and the necessity to stretch an organization's pipeline out beyond patent loss drives stakeholders to demand efficiency gains.
Widening availability of real-world evidence, e.g., electronic medical records, heterogeneous omics data sets, imaging repositories, and digital biomarkers, drives the transformation, making virtual screening and repurposing more efficient. Also, low-cost cloud computing and scalable infrastructure, along with falling prices, render high computational experimentation integration possible, thus enabling an attractive solution in digital transformation to address resource deficiency.
The other strong market enabler is an increase in the willingness of regulatory agencies to computationally enabled candidate selection and trial designs enriched with biomarkers, which decrease the uncertainty that goes with innovation. The pandemic has cemented digital and virtual approaches across the industry, thereby creating investment in computational verification and mixed experimentations The move toward precision medicine highlights the increased significance of stratified and patient-specific approaches, necessitating a focus on computational precision and rapid iteration over conventional empirical techniques.
New entrants to the AI in drug discovery market suggest distinct shift in the use of multi-omics data, in order to make better sense of disease mechanisms. Businesses are utilizing AI in the reconciliation of proteomics, genomics, and metabolomics for insights and enhanced, precise resolution.
AI applied to drug repurposing is now an emergent trend and can be utilized to enable new cases of existing drugs at record speed. Additionally, generative AI models that develop molecular structures into design space are becoming more popular and allow for better hit discovery and for optimization processes to occur faster.
The competitive landscape is maturing, and there is a greater cooperation among all pharmaceutical companies, biotech-startups, and technology companies with the intent of developing commensurate AI-co powered platforms. Collectively, players in the marketplace are pursuing proprietary algorithms, while investing human capital into the design of non-exclusive, design, predictive toxicology, and virtual screening algorithms, ultimately to derive competitive advantages.
For research applications to be trustworthy, the integrity and accuracy of the data have to be effectively ensured to offer reliable inferences and leave a destructive legacy on the community in real world applications. Companies are simultaneously identifying potential partnership opportunities and engaging with academic research institutions or consortia to seize local domain or data diversity expertise.
Firms are also adopting drug discovery cloud solutions and hybrid networking strategies with the goal of establishing and providing a drug discovery, end-to-end ecosystem powered by AI, ensuring its sustainability and provide long-term flexibility.
The use of artificial intelligence (AI) in drug discovery transforms how new medications are created, which are ultimately promoted by governments. Traditional approaches of screening to identify promising new therapeutic candidates can take years and millions of dollars. AI allows researchers to sample large chemical libraries and screening processes in minutes or within hours and predict binding affinities.
The primary advantage of AI in pharmaceutical development is its ability to work with large biological data sets. Researchers are using AI methods to genomic, proteomic, and clinical data to develop biopharmaceuticals in the systems biology context to identify drug targets that can be advanced more rationally, thus, increasing the probability for success.
AI techniques create fresh possibilities for crafting tailored treatments according to the patient's characteristics. In addition to this, AI can then also assist drug development by re-purposing existing drugs, vastly reducing the development timeframe and providing access to life-saving treatments sooner.
AI applications also include drug design optimization and predicting safety profiles. Generative AI models can now design entirely novel molecular structures of interest with the wanted attributes, speeding the innovation pipeline. Predictive algorithms also predict possible side effects, toxicities, and pharmacokinetic behaviours prior to clinical trial initiation. It reduces the risk of late-stage failures and improves the possibilities of success, thus reducing development costs.
AI can also have an important impact on the design of clinical trials, in addition to discovery. AI can focus and enhance studies as it can assist with patient stratification and identify biomarkers. AI-powered platforms are developing end-to-end drug development platforms due to automation and cloud computing. AI is also destined to play a huge role in clinical trial design, as well as in discovery.
| Attribute | Detail |
|---|---|
| AI in Drug Discovery Market Drivers |
|
The growing prevalence of chronic diseases such as, cancer, cardiovascular diseases, diabetes, and neurodegenerative diseases is leading to an increased need for effective therapies. The traditional drug discovery strategy is too slow and expensive in comparison with the unmet need, creating a strong incentive to find efficiencies.
AI is poised to offer ways to speed up candidate identifications, enhance molecular design, and elevate preclinical studies to mitigate the current urgent chronic disease burden. These AI-based platforms are able to access large, expanding datasets created for the study of chronic disease, including genome profiling, clinical data, and biomarker data.
AI can identify associations from the minor opportunities in the subset of data to assist individuals in finding new drug targets, which may lead to drug therapies for diseases that are otherwise not possible to discover through conventional means. This use of AI is important in complex chronic diseases where disease pathways are multifactorial, and advanced tools are required to optimally map out. In this context, AI will improve the chances of targeted therapy possible for the betterment of patient health.
By leveraging knowledge of current drugs, AI identifies new consumables that take much less time to develop. This strategy also offers the possibility of safer therapies; as repurposed drugs already have established safety data.
The relentless increase in chronic diseases provides certainty in drug discovery advances, and subsequently, a direct market development opportunity for AI. Businesses and research institutions are investigating AI to meet the healthcare demands of the growing population, as regulators start moving towards evidence backed by computational power.
Artificial intelligence (AI) and machine learning (ML) are instrumental to the fast growth of the AI in drug discovery industry. Drug development has long been based on an expensive and a slow trial-and-error process, but the rapid evolution of AI software that supports advanced biological simulations has allowed scientists to model realistically complex biological interactions and make apt predictions of the effect of various interventions or sets of interventions within half the time (models are able to simulate tens or even hundreds of thousands of compounds at the same time).
Through their application, scientists are able to harness large and complex biomedical data sets with maximum efficiency, largely machine learning models but particularly deep learning models, with clear applications in biosciences. Such data sets consist of genomic data, proteomics data, and clinical data, all of which form the core of establishing relations that are not strongly discernible among genetic markers, disease pathways, and drug response.
This capability enables the identification of novel targets and ultimately improves compound design. In addition, we can tackle disease models or develop therapeutics for diseases that require consideration of high-dimensional datasets with a complicated set of biological and environmental interactions, with more accurate and novel therapeutics arise.
The second major leap is application of generative AI for designing completely new molecular structures. The growth of ML and AI technology is pivotal to the acceleration of the AI in drug discovery market. The possibility of using those models to predict favorable properties, like solubility and toxicity, prior to lab testing, decrease costs and timelines. Additionally, predictive analytics, using ML, aids in drug safety profiles and pharmacokinetic modeling, potentially reducing late-stage clinical trial failures and guaranteeing increased success rates.
These capabilities will evolve the drug discovery landscape for both - corporate and academic organizations. It will enable comprehensive, end-to-end drug development processes with AI and ML, as it relates to all aspects of virtual screening, compound optimization, and clinical trial design, effectively rushing the timelines and scaling the industry. As these technologies steadily advance in maturity, they will foster further innovation, draw in increased investment, and allow AI to become the leading platform for contemporary drug discovery.
The oncological disorders segment is dominating the AI in drug discovery market due to the immediate need for effective treatments. Cancer involves multifactorial genetic and molecular changes and thus is typical for an AI approach where many different genomic and clinical datasets can be analyzed given these changes rather than with simple logic. AI can aid in identifying new biomarkers, targets, or individualized treatment choices that significantly influence precision oncology.
Moreover, increase in global cancer burden has created additional pressure and allowed for more funding activities to explore the use of AI in drug discovery and accelerate therapeutic development. Using AI enhanced drug discovery, pharmaceutical companies and research organizations can support drug repurposing, predictive modelling and optimizing clinical trials.
| Attribute | Detail |
|---|---|
| Leading Region |
|
North America dominates the AI in drug discovery market because of the countries' strong and stretched technological infrastructure, their advanced healthcare system, and consumer's approval of new technologies. There are a larger number of research institutions, biotech companies, and pharmaceutical companies in the region, and they are investing heavily in upgrading their drug development procedures through using AI platforms. There is a lot of funding available from both - venture capital and government funding, and it strengthens North America further.
Moreover, North America has large biomedical data sets, supportive regulatory system, and there are many collaborative efforts in place between academics, industry, and AI technology developers. Collectively, these components build the innovativeness of the region, and increase the capacity of bringing AI-derived discoveries to market through new therapies.
The companies that are involved in the AI in drug discovery market are undertaking several initiatives including forming strategic partnerships with pharmaceutical and information technology companies, investment in proprietary algorithms, and developing and extending data driven platforms. They also prioritize multi-omics data, generative artificial intelligence for molecular design, and a cloud ecosystem to encourage speed and scalability for drug development.
Merck KGaA, Insilico Medicine, BenevolentAI, Relay Therapeutics, Atomwise Inc., DEEP GENOMICS, ZS, Recursion, Verge Genomics, Benchling, BioAge Labs, Inc., Curia Global, Inc., StoneWise, Genesis Therapeutics, Valo Health, IKTOS, MAbSilico, Elix, Inc., and Google LLC are some of the leading players operating in the global AI in drug discovery market.
Each of these players has been profiled in the AI in drug discovery market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 2.1 Bn |
| Forecast Value in 2035 | US$ 13.2 Bn |
| CAGR | 18.4% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn |
| Biotechnology Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation | Offering Type
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global AI in drug discovery market was valued at US$ 2.1 Bn in 2024
The global AI in drug discovery industry is projected to reach more than US$ 13.2 Bn by the end of 2035
Increasing prevalence of chronic diseases, advancements in AI and machine learning, rising research & development investment, and growth of personalized medicine are some of the factors driving the expansion of AI in drug discovery market.
The CAGR is anticipated to be 18.4% from 2025 to 2035
Merck KGaA, Insilico Medicine, BenevolentAI, Relay Therapeutics, Atomwise Inc., DEEP GENOMICS, ZS, Recursion, Verge Genomics, Benchling, BioAge Labs, Inc., Curia Global, Inc., StoneWise, Genesis Therapeutics, Valo Health, IKTOS, MAbSilico, Elix, Inc., and Google LLC
Table 01: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Offering Type, 2020 to 2035
Table 02: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 03: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 04: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 05: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 06: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Therapeutic Area, 2020 to 2035
Table 07: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 08: Global AI in Drug Discovery Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 09: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 10: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Offering Type, 2020 to 2035
Table 11: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 12: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 13: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 14: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 15: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Therapeutic Area, 2020 to 2035
Table 16: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 17: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 18: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Offering Type, 2020 to 2035
Table 19: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 20: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 21: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 22: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 23: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Therapeutic Area, 2020 to 2035
Table 24: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 25: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 26: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Offering Type, 2020 to 2035
Table 27: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 28: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 29: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 30: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 31: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Therapeutic Area, 2020 to 2035
Table 32: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 33: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 34: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Offering Type, 2020 to 2035
Table 35: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 36: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 37: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 38: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 39: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Therapeutic Area, 2020 to 2035
Table 40: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 41: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 42: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Offering Type, 2020 to 2035
Table 43: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 44: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 45: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 46: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 47: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By Therapeutic Area, 2020 to 2035
Table 48: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Figure 01: Global AI in Drug Discovery Market Value Share Analysis, By Offering Type, 2024 and 2035
Figure 02: Global AI in Drug Discovery Market Attractiveness Analysis, By Offering Type, 2025 to 2035
Figure 03: Global AI in Drug Discovery Market Revenue (US$ Bn), by Software, 2020 to 2035
Figure 04: Global AI in Drug Discovery Market Revenue (US$ Bn), by Services, 2020 to 2035
Figure 05: Global AI in Drug Discovery Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 06: Global AI in Drug Discovery Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 07: Global AI in Drug Discovery Market Revenue (US$ Bn), by Small Molecules, 2020 to 2035
Figure 08: Global AI in Drug Discovery Market Revenue (US$ Bn), by Biologics, 2020 to 2035
Figure 09: Global AI in Drug Discovery Market Value Share Analysis, By Technology, 2024 and 2035
Figure 10: Global AI in Drug Discovery Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 11: Global AI in Drug Discovery Market Revenue (US$ Bn), by Machine Learning, 2020 to 2035
Figure 12: Global AI in Drug Discovery Market Revenue (US$ Bn), by Natural Language Processing, 2020 to 2035
Figure 13: Global AI in Drug Discovery Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 14: Global AI in Drug Discovery Market Value Share Analysis, By Application, 2024 and 2035
Figure 15: Global AI in Drug Discovery Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 16: Global AI in Drug Discovery Market Revenue (US$ Bn), by Target Identification, 2020 to 2035
Figure 17: Global AI in Drug Discovery Market Revenue (US$ Bn), by Target Validation, 2020 to 2035
Figure 18: Global AI in Drug Discovery Market Revenue (US$ Bn), by Preclinical and Clinical Trial Design, 2020 to 2035
Figure 19: Global AI in Drug Discovery Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 20: Global AI in Drug Discovery Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 21: Global AI in Drug Discovery Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 22: Global AI in Drug Discovery Market Revenue (US$ Bn), by Oncological Disorders, 2020 to 2035
Figure 23: Global AI in Drug Discovery Market Revenue (US$ Bn), by Infectious Diseases, 2020 to 2035
Figure 24: Global AI in Drug Discovery Market Revenue (US$ Bn), by Neurological Disorders, 2020 to 2035
Figure 25: Global AI in Drug Discovery Market Revenue (US$ Bn), by Metabolic Disorders, 2020 to 2035
Figure 26: Global AI in Drug Discovery Market Revenue (US$ Bn), by Cardiovascular Disorders, 2020 to 2035
Figure 27: Global AI in Drug Discovery Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 28: Global AI in Drug Discovery Market Value Share Analysis, By End-user, 2024 and 2035
Figure 29: Global AI in Drug Discovery Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 30: Global AI in Drug Discovery Market Revenue (US$ Bn), by Pharmaceutical and Biotechnology Companies, 2020 to 2035
Figure 31: Global AI in Drug Discovery Market Revenue (US$ Bn), by Contract Research Organizations (CROs), 2020 to 2035
Figure 32: Global AI in Drug Discovery Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 33: Global AI in Drug Discovery Market Value Share Analysis, By Region, 2024 and 2035
Figure 34: Global AI in Drug Discovery Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 35: North America - AI in Drug Discovery Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 36: North America - AI in Drug Discovery Market Value Share Analysis, by Country, 2024 and 2035
Figure 37: North America - AI in Drug Discovery Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 38: North America - AI in Drug Discovery Market Value Share Analysis, By Offering Type, 2024 and 2035
Figure 39: North America - AI in Drug Discovery Market Attractiveness Analysis, By Offering Type, 2025 to 2035
Figure 40: North America - AI in Drug Discovery Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 41: North America - AI in Drug Discovery Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 42: North America - AI in Drug Discovery Market Value Share Analysis, By Technology, 2024 and 2035
Figure 43: North America - AI in Drug Discovery Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 44: North America - AI in Drug Discovery Market Value Share Analysis, By Application, 2024 and 2035
Figure 45: North America - AI in Drug Discovery Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 46: North America - AI in Drug Discovery Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 47: North America - AI in Drug Discovery Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 48: North America - AI in Drug Discovery Market Value Share Analysis, By End-user, 2024 and 2035
Figure 49: North America - AI in Drug Discovery Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 50: Europe - AI in Drug Discovery Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 51: Europe - AI in Drug Discovery Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 52: Europe - AI in Drug Discovery Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 53: Europe - AI in Drug Discovery Market Value Share Analysis, By Offering Type, 2024 and 2035
Figure 54: Europe - AI in Drug Discovery Market Attractiveness Analysis, By Offering Type, 2025 to 2035
Figure 55: Europe - AI in Drug Discovery Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 56: Europe - AI in Drug Discovery Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 57: Europe - AI in Drug Discovery Market Value Share Analysis, By Technology, 2024 and 2035
Figure 58: Europe - AI in Drug Discovery Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 59: Europe - AI in Drug Discovery Market Value Share Analysis, By Application, 2024 and 2035
Figure 60: Europe - AI in Drug Discovery Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 61: Europe - AI in Drug Discovery Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 62: Europe - AI in Drug Discovery Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 63: Europe - AI in Drug Discovery Market Value Share Analysis, By End-user, 2024 and 2035
Figure 64: Europe - AI in Drug Discovery Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 65: Asia Pacific - AI in Drug Discovery Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 66: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 67: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 68: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, By Offering Type, 2024 and 2035
Figure 69: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, By Offering Type, 2025 to 2035
Figure 70: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 71: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 72: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, By Technology, 2024 and 2035
Figure 73: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 74: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, By Application, 2024 and 2035
Figure 75: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 76: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 77: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 78: Asia Pacific - AI in Drug Discovery Market Value Share Analysis, By End-user, 2024 and 2035
Figure 79: Asia Pacific - AI in Drug Discovery Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 80: Latin America - AI in Drug Discovery Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 81: Latin America - AI in Drug Discovery Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 82: Latin America - AI in Drug Discovery Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 83: Latin America - AI in Drug Discovery Market Value Share Analysis, By Offering Type, 2024 and 2035
Figure 84: Latin America - AI in Drug Discovery Market Attractiveness Analysis, By Offering Type, 2025 to 2035
Figure 85: Latin America - AI in Drug Discovery Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 86: Latin America - AI in Drug Discovery Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 87 Latin America - AI in Drug Discovery Market Value Share Analysis, By Technology, 2024 and 2035
Figure 88: Latin America - AI in Drug Discovery Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 89: Latin America - AI in Drug Discovery Market Value Share Analysis, By Application, 2024 and 2035
Figure 90: Latin America - AI in Drug Discovery Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 91: Latin America - AI in Drug Discovery Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 92: Latin America - AI in Drug Discovery Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 93: Latin America - AI in Drug Discovery Market Value Share Analysis, By End-user, 2024 and 2035
Figure 94: Latin America - AI in Drug Discovery Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 95: Middle East & Africa - AI in Drug Discovery Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 96: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 97: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 98: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, By Offering Type, 2024 and 2035
Figure 99: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, By Offering Type, 2025 to 2035
Figure 100: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 101: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 102: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, By Technology, 2024 and 2035
Figure 103: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 104: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, By Application, 2024 and 2035
Figure 105: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 106: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 107: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 108: Middle East & Africa - AI in Drug Discovery Market Value Share Analysis, By End-user, 2024 and 2035
Figure 109: Middle East & Africa - AI in Drug Discovery Market Attractiveness Analysis, By End-user, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
AI in Drug Discovery Market